Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroshi Miyama has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictors and incidence of health status deterioration in patients with early atrial fibrillation

    by Hiroshi Miyama, Nobuhiro Ikemura, Takehiro Kimura, Yoshinori Katsumata, Shuhei Yamashita, Koki Yamaoka, Susumu Ibe, Otoya Sekine, Ikuko Ueda, Iwao Nakamura, et al.


  • Open Access

    Assessment of patient characteristics influencing the complexity of leadless pacemaker implantation

    by Hiroshi Miyama, Yukihiro Himeno, Shuhei Yano, Shuhei Yamashita, Koki Yamaoka, Susumu Ibe, Otoya Sekine, Yoshinori Katsumata, Takahiko Nishiyama, Takehiro Kimura, et al.


  • Open Access

    Discontinuation of Oral Anticoagulants in Atrial Fibrillation Patients: Impact of Treatment Strategy and on Patients’ Health Status

    by Ryo Nakamaru, Nobuhiro Ikemura, Takehiro Kimura, Yoshinori Katsumata, Charles F. Sherrod, Hiroshi Miyama, Yasuyuki Shiraishi, Hideaki Kanki, Koji Negishi, Ikuko Ueda, et al.

    Aims: The discontinuation of oral anticoagulants (OACs) remains as a significant concern in the management of atrial fibrillation (AF). The discontinuation rate may vary depending on management strategy, and physicians may also discontinue OACs due to concerns about patient satisfaction with their care. We aimed to assess the incidence of OAC discontinuation and its relationship to patients’ health in an outpatient AF registry. Methods and Results: From a multicenter registry for newly recognized AF patients (n = 3313), we extracted 1647 (49.7%) patients with OACs and a CHA2DS2-Vasc score of ≥2. Discontinuation was defined as sustained cessation of OACs within a 1-year follow-up. We examined predictors associated with discontinuation and its relations to health status defined by the AFEQT questionnaire. Of the 1647 patients, 385 (23.6%) discontinued OACs after 1 year, with discontinuation rates varying across treatment strategies (15.3% for catheter ablation, 4.9% for rhythm control with antiarrhythmic drugs, and 3.0% for rate control). Successful rhythm control was associated with discontinuation in the catheter ablation (OR 6.61, 95% CI 3.00–14.6, p < 0.001) and antiarrhythmic drugs (OR 6.47, 95% CI 2.62–15.9, p < 0.001) groups, whereas the incidence of bleeding events within 1 year was associated with discontinuation in the rate control group. One-year AFEQT scores did not significantly differ between patients who discontinued OACs and those who did not in each treatment strategy group. Conclusions: OAC discontinuation was common among AF patients with significant stroke risk but varied depending on the chosen treatment strategy. This study also found no significant association between OAC discontinuation and patients’ health status.


  • Open Access

    Prognostic Implications and Efficacy of Catheter Ablation by Atrial Fibrillation Type

    by Hiroshi Miyama, Seiji Takatsuki, Nobuhiro Ikemura, Takehiro Kimura, Yoshinori Katsumata, Shuhei Yamashita, Koki Yamaoka, Susumu Ibe, Yuta Seki, Terumasa Yamashita, et al.

    Background: Catheter ablation (CA) for atrial fibrillation (AF) is preferred for paroxysmal AF (PAF) but selectively performed in patients with persistent AF (PersAF). This study aimed to investigate the prognostic differences and consequences of CA based on the AF type. Methods and Results: Data from a multicenter AF cohort study were analyzed, categorizing patients as PAF or PersAF according to AF duration (≤7 or >7 days, respectively). A composite of all‐cause death, heart failure hospitalization, stroke, and bleeding events during 2‐year follow‐up and changes in the Atrial Fibrillation Effect on Quality‐of‐life score were compared. Additionally, propensity score matching was performed to compare clinical outcomes of patients with and without CA in both AF types. Among 2788 patients, 51.6% and 48.4% had PAF and PersAF, respectively. Patients with PersAF had a higher incidence of the composite outcome (12.8% versus 7.2%; P P =0.031) and was associated with poor improvements in Atrial Fibrillation Effect on Quality‐of‐life scores. Propensity score matching analysis showed that the CA group had significantly fewer adverse events than the medication group among patients with PAF (odds ratio, 0.31 [95% CI, 0.18–0.68]; P =0.002). Patients with PersAF showed a similar but nonsignificant trend. Conclusions: PersAF is a risk factor for worse clinical outcomes, including patients' health status. CA is associated with fewer adverse events, although careful consideration is required based on the AF type.


  • Open Access

    Delineation of conduction gaps of linear lesions during atrial fibrillation ablation using ultra-high-density mapping

    by Kenji Hashimoto, Takehiro Kimura, Yuta Seki, Susumu Ibe, Terumasa Yamashita, Hiroshi Miyama, Taishi Fujisawa, Yoshinori Katsumata, Keiichi Fukuda, Seiji Takatsuki

    Linear lesions are routinely created by radiofrequency catheter ablation. Unwanted electrical conduction gaps can be produced and are often difficult to ablate. This study aimed to clarify the characteristics of conduction gaps during atrial fibrillation ablation by analysing bidirectional activation maps using a high-density mapping system (RHYTHMIA). This retrospective study included 31 patients who had conduction gaps along pulmonary vein (PV) isolation or box ablation lesions. Activation maps were sequentially created during pacing from the coronary sinus and PV to reveal the earliest activation site, defined by the entrance and exit. The locations, length between the entrance and exit (gap length), and direction were analysed. Thirty-four bidirectional activation maps were drawn: 21 were box isolation lesions (box group), and 13 were PV isolation lesions (PVI group). Among the box group, nine conduction gaps were present in the roof region and 12 in the bottom region, while nine in right PV and four in left PV among the PVI group. Gap lengths in the roof region were longer than those in the bottom region (26.8 ± 11.8 vs. 14.5 ± 9.8 mm; P = 0.022), while those in right PV tended to longer than those in left PV (28.0 ± 15.3 vs. 16.8 ± 8.0 mm, P = 0.201). The entrances and exits of electrical conduction gaps were separated, especially in the roof region, indicating that epicardial conduction might contribute to gap formation. Identifying the bidirectional conduction gap might indicate the location and direction of epicardial conduction. Bidirectional activation maps for conduction gap at roof and bottom are shown. The length between the entrance and exit (gap length) is longer at roof line than bottom line (26.8 ± 11.8 vs. 14.6 ± 9.8 mm, P = 0.022).


  • Open Access

    Genetic Testing Enables the Diagnosis of Familial Hypercholesterolemia Underdiagnosed by Clinical Criteria: Analysis of Japanese Early-Onset Coronary Artery Disease Patients

    by Hiroshi Miyama, Yoshinori Katsumata, Mizuki Momoi, Genki Ichihara, Taishi Fujisawa, Jin Endo, Takashi Kawakami, Masaharu Kataoka, Shinsuke Yuasa, Motoaki Sano, et al.

    Definitive diagnosis of familial hypercholesterolemia (FH) is paramount for the risk management of patients and their relatives. The present study aimed to investigate the frequency of gene variants contributing to low-density lipoprotein cholesterol (LDL-C) metabolism and their clinical relevance in patients with early-onset coronary artery disease (EOCAD). Among 63 consecutive patients with EOCAD (men LDLR variant had three-vessel disease, were on a statin prescription at baseline, and had stable LDL-C levels; however, the case showed a poor response to the intensification of medication after PCI. Approximately 3.8 of patients with EOCAD harbored variants of gene related to LDL-C metabolism; there were no notable indicators in the patients background or clinical course to diagnose FH. Given the difficulty in diagnosing FH based on clinical manifestations and family history, genetic testing could enable the identification of hidden risk factors and provide early warnings to their relatives.


  • Implications of QRS Prolongation in Patients With Atrial Fibrillation (from a Multicenter Outpatient Registry)

    by Hiroshi Miyama, Nobuhiro Ikemura, Takehiro Kimura, Yoshinori Katsumata, Taishi Fujisawa, Ikuko Ueda, Hideo Mitamura, Koji Negishi, Keiichi Nagami, Keiichi Fukuda, et al.


  • Open Access

    Abnormal Liver Function Tests and Long-Term Outcomes in Patients Discharged after Acute Heart Failure

    by Hiroshi Miyama, Yasuyuki Shiraishi, Shun Kohsaka, Ayumi Goda, Yosuke Nishihata, Yuji Nagatomo, Makoto Takei, Keiichi Fukuda, Takashi Kohno, Tsutomu Yoshikawa

    Abnormal liver function tests (LFTs) are known to be associated with impaired clinical outcomes in heart failure (HF) patients. However, this implication varies with each single LFT panel. We aim to evaluate the long-term outcomes of acute HF (AHF) patients by assessing multiple LFT panels in combination. From a prospective multicenter registry in Japan, 1158 AHF patients who were successfully discharged were analyzed (mean age, 73.9 ± 13.5 years; men, 58%). LFTs (i.e., total bilirubin, aspartate aminotransferase or alanine aminotransferase, and alkaline phosphatase) at discharge were assessed; borderline and abnormal LFTs were defined as 1 and ≥2 parameter values above the normal range, respectively. The primary endpoint was composite of all-cause death or HF readmission. At the time of discharge, 28.7% and 8.6% of patients showed borderline and abnormal LFTs, respectively. There were 196 (16.9%) deaths and 298 (25.7%) HF readmissions during a median 12.4-month follow-up period. The abnormal LFTs group had a significantly higher risk of experiencing the composite outcome (adjusted hazard ratio: 1.51, 95% confidence interval: 1.08–2.12, p = 0.017), whereas the borderline LFTs group was not associated with higher risk of adverse events when referenced to the normal LFTs group. Among AHF patients, the combined elevation of ≥2 LFT panels at discharge was associated with long-term adverse outcomes.


  • Anatomical changes in the pulmonary veins and left atrium after cryoballoon ablation

    by Hiroshi Miyama, Seiji Takatsuki, Kenji Hashimoto, Terumasa Yamashita, Taishi Fujisawa, Yoshinori Katsumata, Takehiro Kimura, Keiichi Fukuda

    Background: The anatomical changes in pulmonary veins (PVs) after cryoballoon ablation (CBA) are unclear. We aimed to determine the morphological changes in the PVs and left atrium (LA) along with the predictive factors for clinical PV stenosis.Methods: We analyzed data of 320 PVs from 80 patients who underwent CBA for atrial fibrillation (age: 62 ± 10 years, 59 males). All patients underwent pre‐ and post‐procedural cardiac computed tomography. We defined clinical PV stenosis when the cross‐sectional area decreased by more than 50%.Results: The average ostial PV area and LA volume decreased significantly after CBA (pre‐ vs post‐CBA; 2.4 ± 1.0 cm2 vs 2.3±1.1 cm2, P < .001, 75.0 ± 23.2 cm3 vs 70.7 ± 21.9 cm3, P < .001, respectively). There was a significant correlation between the reduction rates of the PV area and those of LA volume (R = 0.411, P < .001). The larger preoperative PV area and greater reduction in LA volume were associated with advanced PV narrowing. Clinical PV stenosis was observed in six PVs, was more common in females (male vs female; 0.8% vs 4.8%, P = .043), and tended to be more frequent in left PVs (left PVs vs right PVs; 3.1% vs 0.6%: P = .107), irrespective of the LA volume reduction.Conclusions: The significant reduction of the ostial PV area occurred after CBA, which correlated with the reduction rate of LA volume. The narrowing of the PV was partly produced by the LA volume reduction. Clinical PV stenosis was more common in females and tended to be more frequent in left PVs.


  • Surgical experience of syringomyelia with reference to the findings of magnetic resonance imaging

    by Kazuhiko Kyoshima, Takayuki Kuroyanagi, Toshihide Toriyama, Takeomi Takizawa, Yunoshin Hirooka, Hiroshi Miyama, Akihiko Tanabe, Susumu Oikawa